These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33832976)

  • 21. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 22. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
    Enocsson H; Wirestam L; Dahle C; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma AA; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; van Vollenhoven RF; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken CA; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
    J Autoimmun; 2020 Jan; 106():102340. PubMed ID: 31629628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    J Rheumatol; 2017 Apr; 44(4):452-458. PubMed ID: 28298561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort.
    Quintana R; Pons-Estel GJ; Roberts K; Sacnún M; Serrano R; Nieto R; Conti S; Gervasoni V; Catoggio LJ; Soriano ER; Scolnik M; García MA; Alvarellos A; Saurit V; Berbotto GA; Sato EI; Costallat LTL; Neto EFB; Bonfa E; Xavier RM; de Oliveira E Silva Montandon AC; Molina-Restrepo JF; Iglesias-Gamarra A; Guibert-Toledano M; Reyes-Llerena GA; Massardo L; Neira OJ; Cardiel MH; Barile-Fabris LA; Amigo MC; Silveira LH; Torre IG; Acevedo-Vásquez EM; Ugarte-Gil MF; Alfaro-Lozano JL; Segami MI; Chacón-Díaz R; Esteva-Spinetti MH; Gomez-Puerta JA; Alarcón GS; Pons-Estel BA
    Lupus; 2020 Aug; 29(9):1140-1145. PubMed ID: 32605527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts.
    Frodlund M; Reid S; Wetterö J; Dahlström Ö; Sjöwall C; Leonard D
    Lupus; 2019 Sep; 28(10):1261-1272. PubMed ID: 31296137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
    Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
    J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus.
    Stoll T; Stucki G; Malik J; Pyke S; Isenberg DA
    J Rheumatol; 1997 Feb; 24(2):309-13. PubMed ID: 9034988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe vitamin D deficiency increases the risk for moderate to severe disease activity in Chinese patients with SLE.
    Gao CC; Liu SY; Wu ZZ; Li TF; Gao GM; Liu ZS; Zheng ZH
    Lupus; 2016 Oct; 25(11):1224-9. PubMed ID: 26921268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
    Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB
    Ann Rheum Dis; 2015 Sep; 74(9):1706-13. PubMed ID: 24834926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum uric acid is associated with damage in patients with systemic lupus erythematosus.
    Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cardenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Cucho-Venegas JM; Alfaro-Lozano J; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
    Lupus Sci Med; 2020; 7(1):e000366. PubMed ID: 32153795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
    Sato JO; Corrente JE; Saad-Magalhães C
    Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada.
    Bourré-Tessier J; Clarke AE; Mikolaitis-Preuss RA; Kosinski M; Bernatsky S; Block JA; Jolly M
    J Rheumatol; 2013 Aug; 40(8):1327-33. PubMed ID: 23772082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of incident depression in systemic lupus erythematosus.
    Huang X; Magder LS; Petri M
    J Rheumatol; 2014 Sep; 41(9):1823-33. PubMed ID: 25128512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort.
    Lopez R; Davidson JE; Beeby MD; Egger PJ; Isenberg DA
    Rheumatology (Oxford); 2012 Mar; 51(3):491-8. PubMed ID: 22109798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort.
    Zeña-Huancas PA; Iparraguirre-López H; Gamboa-Cárdenas RV; Reátegui-Sokolova C; Zevallos-Miranda F; Medina-Chinchon M; Pimentel-Quiroz VR; Elera-Fitzcarrald C; Sarmiento-Velasquez O; Cucho-Venegas JM; Alfaro-Lozano JL; Rodríguez-Bellido ZJ; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
    Clin Rheumatol; 2019 Apr; 38(4):1139-1146. PubMed ID: 30539353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.